HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test

Archives of Virology

Volumn 158, Issue 6, 2013, Pages 1143-1149

  Halfon, Philippe ^a,b   Lindemann, Maria Luisa Mateos ^c   Raimondo, Audrey ^a   Ravet, Sophie ^a   Camus, Claire ^a   Khiri, Hacène ^a   Pénaranda, Guillaume ^a   Sideri, Mario ^d   Sandri, Maria Teresa ^d  

^a Laboratoire Alphabio   (France)

^b Hospital Ambroise Pare   (France)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGE; ARTICLE; COLPOSCOPY; FEMALE; GENETICS; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; METHODOLOGY; MOLECULAR DIAGNOSIS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COLPOSCOPY; DNA, VIRAL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 31; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31;

EID: 84878535988     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1584-4     Document Type: Article

References (30)

1. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M (2003) Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95(1): 46-52.
2. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ (2008) Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl 10): K29-K41.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6): 518-527.
4. Woodman CB, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7(1): 11-22.
5. Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5): 342-350.
6. Meijer CJ, Snijders PJ, Castle PE (2006) Clinical utility of HPV genotyping. Gynecol Oncol 103(1): 12-17.
7. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3): 621-632.
8. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) A review of human carcinogens-part B: biological agents. Lancet Oncol 10(4): 321-322.
9. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24 (Suppl 3): S3/1-10.
10. Snijders PJ, van den Brule AJ, Meijer CJ (2003) The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 201(1): 1-6.
11. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE (2009) How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 125: 2489-2496.
12. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97(14): 1072-1079.
13. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D (2007) 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197(4): 346-355.
14. Else EA, Swoyer R, Zhang Y, Taddeo FJ, Bryan JT, Lawson J, van Hyfte I, Roberts CC (2011) Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol 49: 1907-1912.
15. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J (2008) Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17(11): 3033-3042.
16. Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc B (2010) Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomark 7(3): 133-139.
17. Poljak M, Kocjan BJ (2010) Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 8(10): 1139-1162. doi: 10. 1586/eri. 10. 104.
18. Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L, Syrjanen K (2008) Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis 35(5): 521-527.
19. Halfon P, Benmoura D, Khiri H, Penaranda G, Blanc B, Riggio D, Sandri MT (2010) Comparison of the clinical performance of carcinogenic HPV typing of the linear array and Papillocheck HPV-screening assay. J Clin Virol 47(1): 38-42.
20. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL (2011) High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV Study. Am J Clin Pathol 135(3): 468-475.
21. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer CJ, van Doorn LJ, Quint WG (2009) High-throughput genotyping of high-risk HPV by the digene HPV genotyping LQ test using GP5+/6+-PCR and xMAP technology. J Clin Virol 46(Suppl 3): S21-S26.
22. Godinez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, Bravo IG, Bosch FX, de Sanjose S (2011) Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based linear array. Infect Agent Cancer 6: 23. doi: 10. 1186/1750-9378-6-23.
23. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7): 453-459. doi: 10. 1016/S1473-3099(07)70158-5.
24. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3): 147-172. doi: 10. 3322/caac. 21139.
25. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. J Low Genit Tract Dis 16(3): 175-204. doi: 10. 1097/LGT. 0b013e31824ca9d5.
26. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M (2007) Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 197(4): 356 e351-356.
27. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM (2011) Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12(9): 880-890. doi: 10. 1016/S1470-2045(11)70188-7.
28. Sundstrom K, Eloranta S, Sparen P, Arnheim Dahlstrom L, Gunnell A, Lindgren A, Palmgren J, Ploner A, Sanjeevi CB, Melbye M, Dillner J, Adami HO, Ylitalo N (2010) Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 19(10): 2469-2478. doi: 10. 1158/1055-9965. EPI-10-0424.
29. Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B (2010) Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ((R)) HPV assay. J Clin Virol 47: 177-181.
30. Soderlund-Strand A, Eklund C, Kemetli L, Grillner L, Tornberg S, Dillner J, Dillner L (2011) Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol. doi: 10. 1016/j. ajog. 2011. 03. 056.